Small molecule · Antagonist of Ras-binding domain of Ras effector proteins, Raf kinase and phosphatidylinositol 3-kinase (PI3K) · developed by Traws Pharma
Rigosertib (ON 01910.Na) is a synthetic benzyl styryl sulfone analogue that acts as a Ras mimetic. It binds the Ras-binding domain of Ras effector proteins such as Raf kinase and PI3K, preventing Ras from engaging its targets and inhibiting downstream signaling, cell cycle progression and proliferation. It has been studied in advanced solid tumors, hepatoma, and myelodysplastic syndromes.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02562443 | Phase 3 | Myelodysplastic Syndrome | Terminated | TRAW |
| NCT01928537 | Phase 3 | Myelodysplastic Syndromes | Completed | TRAW |
| NCT01241500 | Phase 3 | Myelodysplastic Syndromes | Completed | TRAW |
| NCT01904682 | Phase 2 | Myelodysplastic Syndromes | Completed | TRAW |
| NCT00861783 | Phase 1 | Hepatoma | Completed | TRAW |
| NCT00861328 | Phase 1 | Advanced Solid Tumors | Completed | TRAW |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorChronic Myelomonocytic LeukemiaCytopeniaHepatomaMDSMyelodysplastic SyndromeRAEBRefractory Anemia With Excess Blasts
Updated Nov 1, 2026. Something wrong or missing? Report it on the TRAW page.
See TRAW's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TRAW catalysts and pipeline →